VVI pacing with normal QRS duration and ventricular function: MOST trial findings relevant to leadless pacemakers.

Zak LoringRebecca NorthAnne S HellkampBrett D AtwaterCamille G Frazier-MillsKevin P JacksonSean D PokorneyGervasio A LamasJonathan P Piccini

Published in: Pacing and clinical electrophysiology : PACE (2020)

In patients without reduced LVEF or prolonged QRSd who would be eligible for LP, DDDR, and VVIR pacing demonstrated similar rates of death, stroke or HF hospitalization; however, VVIR pacing significantly increased the risk of AF development.

Keyphrases

cardiac resynchronization therapy
end stage renal disease
atrial fibrillation
left ventricular
heart failure
chronic kidney disease
clinical trial
study protocol
randomized controlled trial
phase iii
patient reported outcomes
patient reported
blood brain barrier
subarachnoid hemorrhage